Studying tumor DNA and proteins in pancreatic cancer
Part of Cancer clinical trials.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with resectable, borderline resectable, or locally advanced pancreatic cancer (not spread to distant organs).
- You are enrolled in the Personalized Oncogenomics program at BC Cancer.
- You are healthy enough to undergo surgery and chemotherapy as planned.
- You have good blood counts and organ function (kidneys, liver, blood clotting).
- You have not started chemotherapy for this cancer yet, unless it was given before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing chemotherapy based on a SMAD4 gene change in your tumor works better than the usual approach for pancreatic cancer that can be surgically removed. If you have the gene change, you may get a different chemotherapy combination to improve outcomes.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.